HILE(SH:603718)2025-04-21 08:10Financial Performance - The company's operating revenue for Q1 2025 was RMB 61,792,980.19, a decrease of 12.11% compared to RMB 70,304,397.74 in the same period last year[4]. - Net profit attributable to shareholders was RMB 10,901,715.10, a significant turnaround from a loss of RMB 3,719,366.81 in the previous year[4]. - The net profit after deducting non-recurring gains and losses was RMB 9,199,267.30, compared to a loss of RMB 5,290,448.88 last year, marking a substantial improvement[4]. - The basic earnings per share increased to RMB 0.02 from a loss of RMB 0.01 in the same period last year, reflecting a 300% increase[4]. - Operating profit for Q1 2025 was ¥20,928,778.23, a significant improvement from a loss of ¥5,513,186.84 in Q1 2024[22]. - Net profit for Q1 2025 reached ¥17,937,326.16, compared to a net loss of ¥4,361,103.22 in Q1 2024[22]. - Basic earnings per share for Q1 2025 was ¥0.02, recovering from a loss of ¥0.01 in Q1 2024[23]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 1,833,322,547.46, a slight increase of 0.35% from RMB 1,826,839,219.54 at the end of the previous year[5]. - The total assets as of March 31, 2025, amounted to CNY 1,833,322,547.46, a slight increase from CNY 1,826,839,219.54 on December 31, 2024[17]. - The company reported a total of CNY 678,355,838.27 in current assets, down from CNY 691,774,180.51, indicating a decrease of about 1.9%[17]. - The total liabilities decreased to CNY 106,521,032.35 from CNY 123,645,731.78, representing a reduction of about 13.9%[19]. - The equity attributable to shareholders increased to CNY 1,577,050,799.05 from CNY 1,560,478,382.76, showing an increase of approximately 1.1%[19]. Cash Flow - The net cash flow from operating activities was negative at RMB -5,599,908.01, worsening from RMB -1,229,734.74 in the previous year[4]. - Cash flow from operating activities in Q1 2025 was negative at -¥5,599,908.01, compared to -¥1,229,734.74 in Q1 2024[25]. - Cash flow from investing activities generated ¥20,094,616.04 in Q1 2025, contrasting with a negative cash flow of -¥68,810,882.78 in Q1 2024[25]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥362,240,931.99, up from ¥56,618,265.57 at the end of Q1 2024[26]. Investments and Acquisitions - The company completed the acquisition of 70% of Guizhou Lucheng Biological Technology Co., Ltd. for RMB 22.4 million, enhancing its capabilities in the in vitro diagnostic materials sector[14]. - The company’s long-term investments in fixed assets rose to CNY 29,844,251.25 from CNY 29,045,175.02, an increase of approximately 2.7%[18]. - The company reported a significant increase of 88.05% in net profit after deducting non-recurring gains and losses, amounting to RMB 11,710,828.55 when excluding stock incentive expenses[5]. Cost Management - Total operating costs for Q1 2025 were ¥41,355,751.57, down 48% from ¥79,483,781.34 in Q1 2024[22]. - The company reported a significant reduction in management expenses, from ¥21,100,810.08 in Q1 2024 to ¥11,291,949.78 in Q1 2025, a decrease of approximately 46.6%[22]. Other Financial Metrics - The weighted average return on net assets rose to 0.70%, an increase of 1 percentage point from -0.30% last year[5]. - The company completed the cancellation of 2,237,800 restricted shares, reducing the total number of restricted shares to 6,682,500[16]. - The company achieved a net investment income of ¥284,477.72 in Q1 2025, down from ¥857,854.31 in Q1 2024[22].